Mustang Bio Inc MBIO
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2017-08-22 |
| Shares Out. | 7,580,000 |
| Website | mustangbio.com/ ↗ |
| Phone | 13025310855 |
| Employees | 4 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$1.1M |
| Free Cash Flow | -$4.5M |
| Total Assets | $15.6M |
| Total Liabilities | $8.1M |
| Equity | $7.5M |
About Mustang Bio Inc
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Mustang Bio Inc is a publicly traded company under the ticker symbol MBIO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2024-12-01)